PTO/SB/05e (12-08)
Approved for use through 01/31/2009 OMB 0651-0001
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION D	ISCLOSURE
STATEMENT BY	APPLICANT
(Not for submission un	der 37 CFR 1.99

Application Number		10658873
Filing Date		2003-09-05
First Named Inventor	Micha	ael S. Kopreski
Art Unit		1634
Examiner Name Lu, Fr		rank Wei Min
Attorney Docket Numb	er	00-1312-K

					U.S.I	PATENTS			Remove			
Examiner C Initial* N		Patent Number	Kind Code ¹	Issue D	ate	Name of Pate of cited Docu	entee or Applicant iment	Releva		Lines where ges or Relev		
	1											
If you wisl	h to a	i dd additional U.S. Pate	nt citatio	n informa	ation pl	l lease click the	Add button.	_	Add			
			U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove			
Examiner Cite Publication Num		Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant Releva				Lines where ges or Relev		
	1											
If you wisl	h to a	dd additional U.S. Publ	ished Ap	plication	citation	n information p	olease click the Ad	d button	=			
				FOREIG	N PAT	ENT DOCUM	IENTS		Remove		_	
		Country Kind Code ² i Code ⁴			Publication Date	e or	vhere Rel	or Relevant	т.			
	1										Г	
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	lease click the Add	button	Add		_	
			NON	I-PATEN	IT LITE	RATURE DO	CUMENTS		Remove			
Examiner Initials*	Cite No	Include name of the a (book, magazine, jour publisher, city and/or	nal, seri	al, sympo	osium,	catalog, etc), o					Тв	

1	1	Rajagopal et al. (1995), Int. J. Cancer 62: 661-667.	
:	2	Dahiya et al. (1996), Urology 48: 963-970.	
3	3	LeRiche et al. (1996), J. Cim. Endocrinot. Metab. 81: 656-662.	
4	ı	Pfeiffer et al. (1997), Int. J. Cancer 72: 581-586.	
	5	De Luca et al. (2000), Clin. Cancer Res. 6: 1439-1444.	
	6	Schlegel et al. (1994), Int. J. Cancer 56: 72-77.	
1	7	Worm et al. (1999), Hum. Pathol. 30: 222-227.	
8	В	Pawlowski et al. (2000), Cancer Detect. Prev. 24: 212-223.	
5	9	Walch et al. (2001), Lab. Invest. 81: 791-801.	
	10	Sarkar et al. (1983), Diagn. Mol. Pathol. 2: 210-218.	
	11	Gehharrif et al. (1998). Binchem. Binches. Res. Comm. 247-319-323.	П

	Application Number		10658873		
	Filing Date		2003-09-05	Ī	
INFORMATION DISCLOSURE	First Named Inventor	Micha	ael S. Kopreski		
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1634		
(Not for Submission under 37 GFR 1.33)	Examiner Name	Lu, Fr	rank Wei Min		
	Attorney Docket Numb	er	00-1312-K		
	-				

	12	Revillion et al. (1997), Clin. Chem. 43: 2114-2120.	
	13	Schneeberger et al. (1996), Anticancer Res. 16: 849-852.	
	14	Kraehn et al. (2001), Br. J. Cancer 84: 72-79.	
	15	Gamberi et al. (1998), Oncology 55: 556-563.	
	16	Sagawa et al. (2001), Cancer Letters 168: 45-50.	
	17	Christoph et al. (1999). Int. J. Cancer 84: 169-173.	
	18	Latil et al. (2000), Int. J. Cancer 99: 172-176.	
	19	Zhou et al. (1996), J. Biol. Chem. 271: 10760-10766.	
	20	Kozu et al. (1895), Genomics 25: 365-371.	
	21	Cocke et al. (2001), Clin. Chem. 47: 369, abstract 51.	
	22	Poon et al. (2001), Clin. Chem. 47: 363, abstract 11.	П

Application Number | 10658873 |
Filing Date | 2003-09-05 |
Filing Date | 20

	23	Umovitz et al. (1999), Clin. Diag. Lab. Immunology 6: 330-335.	
	24	Zhao et al. (1994), Circulation 90: 677-685.	
	25	Dhillon et al. (2001), Exp. Neurol. 170: 140-148.	
	26	Fleischhacker et al. (2001), Clm. Chem. 47: 369 (Oral Presentation).	×
	27	El-Hefnawy et al. (2004), Clin. Chem. 50(3): 584-573.	
	28	Tschentscher et al. (2000), Int. J. Cim. Lab. Res. 30(1): 13-15.	
	29	Missov et al. (1999), Clinica Chimica Acta 284: 175-185.	
	30	Sarko et al. (2002), J. Emerg. Med. 23(1): 57-65.	
	31	Jurlander et al. (2000), Eur. Heart J. 21: 382-289.	
	32	Rainer et al. (2003), Clin. Chem. 50(1): 206-208.	
ĺ	33	Townsend et al. (1995), J. Mol. Cell. Cardiol. 27: 2223-2236.	П

	Application Number		10658873		
	Filing Date		2003-09-05		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Micha	el S. Kopreski		
(Not for submission under 37 CFR 1.99)	Art Unit		1634		
(Not for Sabilission and of or of it 1.55)	Examiner Name Lu, Frank Wei Min				
	Attorney Docket Numb	er	00-1312-K		

34	Mizuno et al. (2001), Blood 97(5): 1172-1179.	
35	Meiki et al. (1996), Leukemia 12: 311-316.	
36	Lee et al. (1996), Proc. Natl. Acad. Sci. U. S. A. 93: 10366-10370.	
37	Eads et al. (1999), Cancer Res. 59: 2302-2306.	
38	Robertson et al. (1999), Nucleic Acids Res. 27(11): 2291-2298.	
39	Fleischhacker and Schmidt (2007), Biochlin. Biophys. Acta 1775: 181-232.	
40	Lion et al. (1995), Leukenna 9: 1353-1360.	
41	El-Deiry, et al. (1991), Proc. Natl. Acad. Soi. U. S. A. 88: 3470-3474.	
42	Lo et al. (1999), Clin. Chem. 45(8): 1292-1294.	
43	Chen et al. (1999), Int. J. Canoer 83: 10-14.	
44	Sailo et al. (2001), Hepatology 33: 561-568.	П

	45	Wong et al., An Optimised prolocol for the extraction of non-viral mRNA from human plasma frozen for three years," J. Clin. Pathol 57:766-768 (2004).	
	46	Tsui et al., "Stability of Endogenous and Added RNA in Blood Specimens, Serum and Plasma," Clin. Chem. 48(10) 1647-53 (2002).	
	47	Zhou et al., "Croulating RNA as a novel tumor marker. An in vitro study of the origins and characteristics of extracellular RNA." Cancer Letter 259:50-60 (2008).	
If you wis	h to a	dd additional non-patent literature document citation information please click the Add button Add	1

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Table Kind Code of USPTO Patent Documents at wave <u>USPTO GOV</u> or MPEP 90.04. I Enter office that issued the document, by the two-letter code (WIPO Standard ST.3.). For <u>Upperson</u> patent document, by the two-letter code (WIPO Standard ST.3.). For <u>Upperson</u> patent document is set and in the serial number of the patent document. The patent document is set and the patent document is set and the patent document. The patent document is set and the patent document is patent document. The patent document is patent document in the patent document is patent and the patent document is patent document in the patent document is patent document. The patent document is patent document in the patent document is patent document. The patent document is patent document in the patent document is patent document in the patent document is patent document. The patent document is patent document in the patent document is patent document in the patent document in the patent document is patent document in the patent documen